Trial Profile
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Peripheral T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms Ro-CHOP
- 09 Jan 2023 Status changed from active, no longer recruiting to completed.
- 29 Nov 2021 Results published in the Journal of Clinical Oncology
- 08 Dec 2020 Primary endpoint (Progression Free Survival) has not been met, as per results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology